Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 27.5 percent. This is a 108.29 percent decrease over earnings of $3.50 per share from the same period last year. The company reported quarterly sales of $516.000 thousand which missed the analyst consensus estimate of $2.850 million by 81.89 percent. This is a 99.47 percent decrease over sales of $98.149 million the same period last year.